A randomized controlled study showed that in patients with metastatic colorectal cancer receiving first-line combined chemotherapy, the upregulation of plasma TIMP-1 indicates that the objective effective rate of chemotherapy is very low (Sørensen et al., 2007). The gene discussed is TIMP1; the disease is metastatic colorectal cancer.